Brolucizumab Treatment For Pigment Epithelial Detachment In Treatment-Resistant Neovascular Age Related Macular Degeneration
Latest Information Update: 23 Mar 2021
At a glance
- Drugs Brolucizumab (Primary)
- Indications Choroidal neovascularisation; Wet age-related macular degeneration
- Focus Therapeutic Use
- Sponsors Novartis
- 23 Mar 2021 New trial record